Navigation Links
Sangamo BioSciences to Acquire Ceregene
Date:8/26/2013

f DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs their applications in research and the treatment of disease, integration of AAV-based technology and know-how in the development of ZFP Therapeutics and the closing of the acquisition of Ceregene.  Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of our clinical trials, whether the clinical trials will validate and support the tolerability and efficacy of ZFNs, technological challenges, Sangamo's ability to develop commercially viable products, risks associated with the protection of our proprietary technology, technological developments by our competitors, developments at Ceregene after the signing of the definitive agreement and the integration of Ceregene's assets into Sangamo. For a more detailed discussion of these and other risks, please see Sangamo's SE
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
2. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
3. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
4. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
5. Sangamo BioSciences Reports First Quarter 2013 Financial Results
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
9. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
10. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
11. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... N.C. , April 17, 2015 ... the Integrated Embolic Protection™ filter platform for angioplasty ... of a $5.6 million Series B financing round ... venture firm with a focus on medical devices, ... The round also included Mountain Group Partners, Lookout ...
(Date:4/17/2015)... CHICAGO, Ill. , April 17, 2015  AbbVie Inc. ... today announced that it has extended the expiration of its ... common stock of Pharmacyclics, Inc. to 5 p.m., ... On April 17, 2015, AbbVie also voluntarily ... Antitrust Improvements Act in order to provide the FTC with ...
(Date:4/17/2015)... April 17, 2015 Inivata, a ... today that their presence at the 2015 American Association for ... by co-founder Nitzan Rosenfeld and a poster presentation. ... 18 th - 22 nd . The ... ctDNA , forms part of a session on ...
Breaking Medicine Technology:Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 2AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 4Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2
... survival advantage ... standard therapy, -- First study to show survival advantage ... Pharmion Corporation,(Nasdaq: PHRM ) today announced that the ... approval of Thalidomide,Pharmion(R) for use in combination with melphalan and ...
... Appoints U.S. Biotest to Oversee Trials, PRINCETON, ... Board: DSCI), a provider of advanced wound care ... services agreement with San,Luis Obispo-based, privately held U.S. ... of DSC127, a novel and rapid wound-healing and,scar-reduction ...
Cached Medicine Technology:Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 2Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 4Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 5Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 6Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Body's Own Naturally Occurring Stem Cells 2Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Body's Own Naturally Occurring Stem Cells 3Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Body's Own Naturally Occurring Stem Cells 4
(Date:4/17/2015)... April 17, 2015 Alcohol and Violence ... (NCADD) notes that drinking and driving has been the ... the same time, the link between alcohol and crime ... abuse and violence and sexual assault, and their relationship ... the NCADD, 5.3 million adults in America were drinking ...
(Date:4/17/2015)... Sulphur Springs, Texas (PRWEB) April 17, 2015 ... (TLW) four years ago, the Texas non-profit organization has empowered ... part of its effort to bring fresh water and ... recently partnered with Liberty University. Between March 17 and 27, ... which will provide 7,000 Liberians with fresh water and the ...
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
(Date:4/17/2015)... California (PRWEB) April 17, 2015 At ... Entertainment’s EcoLuxe Lounge and the “Salute to the Oscars” ... luxurious Beverly Hilton Hotel, overlooking the impressive Los Angeles ... were organized by Debbie Durkin, LA’s leading producer of ... Showcasing many of the world’s premier providers of eco-friendly ...
(Date:4/17/2015)... Baptist Health and The University of Texas ... designed to transform oncology care in northeast Florida and ... create a joint cancer program to enhance patient access ... MD Anderson Cancer Center is anticipated to open in ... highly coordinated, multidisciplinary cancer care for adults in the ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3
... MYL ),today announced that Mylan Pharmaceuticals Inc. has ... (FDA) for its Abbreviated New,Drug Application (ANDA) for Cetirizine ... HCl Tablets are the generic version of Pfizer,s Zyrtec(R),Tablets, ... the 12,months ending Sept. 30, 2007., This product ...
... 28, 2007 Laser surgery to correct vision problems ... Keratotomy (PRK) is typically used to correct low to ... for high myopia corrections. Although over 18 million LASIK ... controversy regarding the maximum correction possible and efficacy with ...
... patients than are other doctors, study finds , , THURSDAY, ... of spirituality and faith when interacting with patients, but ... finds. , In fact, more than 90 percent of ... ask patients about their religious faith or spirituality, while ...
... 27 The National Drug,Intelligence Center (NDIC), ... and,the nation,s principal center for strategic drug ... Assessment. This strategic,assessment presents an analysis of ... distribution, and abuse in the,United States. The ...
... Dec. 27 Like a lot of Americans, ... healthier your New Year,s resolution -- but,it,s important ... off by January,2nd., Listen to this report ... can access video, audio, text, graphics and,photos for ...
... Practice in Hudson is the Only Accredited Lab in Summit County ... ... Dec. 27 Western Reserve Heart Care, a,cardiology testing and treatment ... echocardiography lab by the,Intersocietal Commission for the Accreditation of Echocardiography,Laboratories (ICAEL)., ...
Cached Medicine News:Health News:LASIK works well, according to long-term study of highly myopic patients 2Health News:Most Psychiatrists Open to Discussing Spiritual Concerns 2Health News:Most Psychiatrists Open to Discussing Spiritual Concerns 3Health News:National Drug Intelligence Center Releases 2008 National Methamphetamine Threat Assessment 2Health News:Western Reserve Heart Care Receives ICAEL Echocardiography Accreditation 2
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
The Plasmacup SC satisfies two important requirements: high primary stability and a low friction bearing surface....
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
Medicine Products: